<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01399151</url>
  </required_header>
  <id_info>
    <org_study_id>WHNRC 213949-1</org_study_id>
    <secondary_id>USDA CRIS 5306-51530-018-00D</secondary_id>
    <nct_id>NCT01399151</nct_id>
  </id_info>
  <brief_title>Assessment of Vitamin D Supplementation and Immune Function</brief_title>
  <acronym>FL-82</acronym>
  <official_title>Assessment of Vitamin D Supplementation and Immune Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>USDA, Western Human Nutrition Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

      Volunteers with vitamin D insufficiency (serum 25(OH)D 25-50 nmol/L) given intermediate or
      high dose vitamin D supplements (2,000 or 5,000 IU per day) will have increased production of
      anti-bacterial peptides and interleukin-1, decreased production of other pro-inflammatory
      cytokines, increased production of regulatory cytokines and an enhanced T- and B-cell
      response to a tetanus vaccine compared to vitamin D insufficient subjects given low dose
      vitamin D supplements (400 IU per day).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aim 1:

      Determine if high dose vitamin D supplements decrease the production of proinflammatory and
      increase the production of regulatory cytokines and chemokines by innate immune cells
      stimulated ex vivo.

      Specific Aim 2:

      Determine if high dose vitamin D supplements decrease serum markers of inflammation and
      increase serum and cellular levels of defensive molecules (e.g., cathelicidin).

      Specific Aim 3:

      Determine if high dose vitamin D supplements decrease blood levels of proinflammatory
      T-helper type 1 (Th1) and Th17 cells and increase levels of anti-inflammatory T-regulatory
      (Treg) and Th2 cells.

      Specific Aim 4:

      Determine if high dose vitamin D supplements increase antigen specific T cell and B cell
      responses after tetanus vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cathelicidin levels in granulocytes</measure>
    <time_frame>0, 8, and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cytokine levels from stimulated Periferal Blood Mononuclear Cells</measure>
    <time_frame>0, 8 and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum cytokines and acute phase proteins</measure>
    <time_frame>0, 8 and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in markers of response to tetanus vaccination</measure>
    <time_frame>0, 8, 9, 10 and 12 weeks</time_frame>
    <description>Markers of response to tetanus vaccine include tetanus-specific proliferation and production of cytokines by CD4 T-helper cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum 25OH Vitamin D</measure>
    <time_frame>0, 4, 8, and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in urinary calcium-to-creatinine ratio</measure>
    <time_frame>0, 2, 4, 6, 8 and 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in level of 5-lipoxygenase protein in granulocytes</measure>
    <time_frame>0, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in production of leukotrienes in granulocytes</measure>
    <time_frame>0, 8, and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D - Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 IU/day Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D- Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,000 IU/day Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D- Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5,000 IU/day Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D - Treatment 1</intervention_name>
    <description>Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.</description>
    <arm_group_label>Vitamin D - Treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D - Treatment 2</intervention_name>
    <description>Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.</description>
    <arm_group_label>Vitamin D- Treatment 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D - Treatment 3</intervention_name>
    <description>Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.</description>
    <arm_group_label>Vitamin D- Treatment 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-49 (men) and 20-45 (women)

          -  BMI 18.5-30

          -  Serum 25OH Vitamin D 25-50 nmol/L

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Daily smoker

          -  Anemia (Hgb&lt;12 mg/dL for women and &lt;13 mg/dL for men) determined at initial visit

          -  Any report or diagnosis of disease or chronic condition that may affect vitamin D
             absorption such as cystic fibrosis, celiac disease, surgical removal of part of the
             stomach or intestines, and some forms of liver disease

          -  Diagnosis of hyper parathyroidism and chronic granulomatous disease, which increases
             risk of hypercalcemia.

          -  Planned to travel to a location at which either altitude or latitude would result in
             significant vitamin D synthesis during the study period.

          -  Not previously vaccinated with TT, or vaccinated within five years

          -  Use of steroids or antibiotics within the past 4 weeks

          -  Current use of nutritional supplements that may alter immune function such as omega 3
             fatty acid supplements

          -  Current use of anti-inflammatory or anti-convulsion medications

          -  Self reported history of significant adverse response to previous vaccinations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Stephensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WHNRC, ARS, University of California Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Human Nutrition Center, University of California Davis</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ars.usda.gov/Main/docs.htm?docid=11240</url>
    <description>USDA Western Human Nutrition Research Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2011</study_first_submitted>
  <study_first_submitted_qc>July 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2011</study_first_posted>
  <last_update_submitted>April 21, 2014</last_update_submitted>
  <last_update_submitted_qc>April 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Immune function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

